PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-term Outcomes and Toxicity.

Abstract Definitive chemoradiation (CRT) is a common approach for locally advanced hypopharyngeal squamous cell carcinoma (SCC) with the goal of organ preservation. Reports on long-term oncologic and functional outcomes have been limited. This study reports on outcomes utilizing this approach at a single institution over 30 years.
PMID
Related Publications

Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer.

Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas.

Primary Surgery vs Chemoradiation Treatment of Advanced-Stage Hypopharyngeal Squamous Cell Carcinoma.

A retrospective study on combined modality therapy with or without surgery for advanced hypopharyngeal squamous cell carcinoma: an analysis of 119 cases.

Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.

Authors

Mayor MeshTerms
Keywords

Head and Neck cancer

chemotherapy

hypopharynx

organ preservation

radiotherapy

squamous cell carcinoma

Journal Title anticancer research
Publication Year Start




PMID- 29848708
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20180611
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 6
DP  - 2018 Jun
TI  - Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the
      Hypopharynx: Long-term Outcomes and Toxicity.
PG  - 3543-3549
LID - 10.21873/anticanres.12626 [doi]
AB  - BACKGROUND/AIM: Definitive chemoradiation (CRT) is a common approach for locally 
      advanced hypopharyngeal squamous cell carcinoma (SCC) with the goal of organ
      preservation. Reports on long-term oncologic and functional outcomes have been
      limited. This study reports on outcomes utilizing this approach at a single
      institution over 30 years. MATERIALS AND METHODS: Medical records for patients
      with stage III-IVB SCC of the hypopharynx were retrospectively reviewed. Patient 
      and disease-related factors were identified and analyzed for impact on overall
      survival (OS), cancer-specific survival (CSS), disease-free survival, distant
      failure, and locoregional failure. RESULTS: A total of 54 patients were
      identified who were treated with definitive CRT to a mean dose of 72 Gy. With a
      median follow-up period of 49.8 months, 5- and 10-year OS was 62% and 43%
      respectively. Five and 10-year CSS were 74% and 72% respectively. Ten-year local 
      control was 78%. Of the 37 patients with no treatment failure, 29% experienced a 
      grade 3 or higher late toxicity, with the majority resolving during continued
      long-term follow-up. CONCLUSION: This study demonstrates good outcomes with
      long-term follow-up with acceptable rates of late toxicities. The findings here
      represent the longest published median follow-up in this population and validate 
      the strategy of organ preservation.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Juloori, Aditya
AU  - Juloori A
AD  - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A. [email protected]
FAU - Koyfman, Shlomo A
AU  - Koyfman SA
AD  - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A.
FAU - Geiger, Jessica L
AU  - Geiger JL
AD  - Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland
      Clinic, Cleveland, OH, U.S.A.
FAU - Joshi, Nikhil P
AU  - Joshi NP
AD  - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A.
FAU - Woody, Neil M
AU  - Woody NM
AD  - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A.
FAU - Burkey, Brian B
AU  - Burkey BB
AD  - Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A.
FAU - Scharpf, Joseph
AU  - Scharpf J
AD  - Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A.
FAU - Lamarre, Eric L
AU  - Lamarre EL
AD  - Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A.
FAU - Prendes, Brandon
AU  - Prendes B
AD  - Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A.
FAU - Adelstein, David J
AU  - Adelstein DJ
AD  - Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland
      Clinic, Cleveland, OH, U.S.A.
FAU - Greskovich, John F
AU  - Greskovich JF
AD  - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A.
FAU - Keller, Lanea
AU  - Keller L
AD  - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic,
      Cleveland, OH, U.S.A.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/pathology/*therapy
MH  - Chemoradiotherapy/adverse effects/methods
MH  - Febrile Neutropenia/etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypopharyngeal Neoplasms/pathology/*therapy
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Osteonecrosis/etiology
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Head and Neck cancer
OT  - chemotherapy
OT  - hypopharynx
OT  - organ preservation
OT  - radiotherapy
OT  - squamous cell carcinoma
EDAT- 2018/06/01 06:00
MHDA- 2018/06/12 06:00
CRDT- 2018/06/01 06:00
PHST- 2018/04/01 00:00 [received]
PHST- 2018/04/30 00:00 [revised]
PHST- 2018/05/03 00:00 [accepted]
PHST- 2018/06/01 06:00 [entrez]
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
AID - 38/6/3543 [pii]
AID - 10.21873/anticanres.12626 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jun;38(6):3543-3549. doi: 10.21873/anticanres.12626.